For adults whose triglyceride levels sit far above the normal range, the danger has never really been the number on a lab report. It has been the pancreas. A sudden, severe inflammation of that organ can put a person in the hospital for weeks, cause permanent damage, and occasionally kill.
There is now a treatment approved specifically to lower that risk. The Food and Drug Administration cleared Tryngolza, known generically as olezarsen, for adults with severe hypertriglyceridemia, defined as fasting triglycerides of at least 500 mg/dL. It is the first therapy in the United States carrying a labeled indication to reduce acute pancreatitis risk in this group.
The approval came in late June, and the drug reached U.S. pharmacies in July. It has not been widely covered in consumer health media, which matters because the affected population is not small. The manufacturer estimates more than three million U.S. adults live with severe hypertriglyceridemia, including roughly one million considered high risk.
The Endpoint That Sets This Approval Apart
Most cholesterol and triglyceride drugs are approved on the basis of moving a laboratory number. Regulators accept that because the number is an established risk marker. What they do not usually get is direct evidence that the drug prevents the specific complication patients fear.
Here they did. According to the FDA's approval announcement, the agency approved the drug both to reduce triglycerides and to reduce the risk of acute pancreatitis, used alongside diet. The FDA notes that guidelines already recommend lowering triglycerides above 500 mg/dL precisely to reduce that risk, that normal levels sit below 150 mg/dL, and that earlier triglyceride-lowering drugs never accumulated enough pancreatitis cases in their trials to demonstrate a reduction.
Acute pancreatitis is not a minor event. It causes severe abdominal pain, frequently requires prolonged hospitalization, and can lead to lasting organ damage. People who have had one episode face higher odds of another.
Archna Bajaj, an assistant professor of clinical medicine at the University of Pennsylvania, said in materials distributed by the manufacturer that patients often cannot get below the 500 mg/dL threshold despite existing therapies and lifestyle changes, which "leaves them at risk of a devastating and potentially life-threatening acute pancreatitis attack."Her comments came with the company's launch announcement, which is relevant context for how they were framed.
Inside the Two Trials
The approval rested on two Phase 3 trials, CORE and CORE2, run with the TIMI Study Group. Together they enrolled 1,061 adults with severe hypertriglyceridemia, according to the FDA, and the average baseline triglyceride level across the two studies was 1,116 mg/dL. Participants received 50 mg or 80 mg of the drug, or placebo, by injection under the skin every four weeks for a year. All were already on standard therapies.
At six months, placebo-adjusted triglyceride reductions ranged from roughly 49 to 63 percent on the lower dose and 55 to 72 percent on the higher dose. At twelve months, the manufacturer reported an 85 percent pooled reduction in acute pancreatitis events, and said that 86 percent of treated patients with data at both time points reached triglycerides below 500 mg/dL. Those pancreatitis figures come from the company rather than the FDA announcement, which described the reduction without attaching a number.
Those are meaningful results, and they deserve two qualifiers. The pancreatitis finding comes from trials designed primarily around triglyceride reduction, and the absolute number of pancreatitis events in any twelve-month trial is small even when the relative reduction is large. Longer follow-up will show whether the effect holds.
Safety signals were not absent. The prescribing information lists injection-site reactions and liver enzyme increases as the most common adverse reactions in this population, with liver enzyme rises reported more often at the 80 mg dose. The label also warns that the drug can raise liver fat and that hypersensitivity reactions requiring medical treatment have occurred.
Who the Drug Is Actually For
This is not a treatment for ordinary elevated triglycerides. The threshold is 500 mg/dL, which is roughly three times the upper end of normal, and most people with mildly high triglycerides will never approach it.
The drug works by targeting apolipoprotein C-III, a liver protein that regulates how the body clears triglycerides. Blocking its production increases clearance. It was already approved in December 2024 for familial chylomicronemia syndrome, a rare inherited form of the condition, and the manufacturer described the broader indication as a historic advance. That is the company's own characterization.
People most likely to be candidates are those whose triglycerides stay above the threshold despite existing medication and lifestyle changes, and particularly those with a prior pancreatitis episode. Uncontrolled diabetes, heavy alcohol use, certain medications, kidney disease, and inherited lipid disorders can all push levels into this range, and a clinician needs to sort out which factors apply before adding a new drug.
Anyone with severe abdominal pain radiating to the back, especially with nausea, vomiting or fever, should seek emergency evaluation. That combination can signal acute pancreatitis and is not something to wait out at home.
Access, Cost, and the Questions Worth Asking
The drug is a once-monthly self-administered injection using an autoinjector, in 50 mg or 80 mg strengths, after training on proper technique. It does not require an infusion center.
Cost is the open question. The manufacturer has not published a consumer-facing list price that could be verified for this report, and specialty injectables in this category typically carry prior authorization requirements. The company has said it offers insurance support and financial assistance programs for people prescribed the drug.
Patients considering it can ask a clinician three concrete things. Whether their most recent fasting triglyceride reading actually meets the 500 mg/dL threshold. Whether a reversible cause such as uncontrolled blood sugar, a medication, or alcohol intake is driving the number. And what their plan requires before approving a specialty injectable. The two pivotal studies, CORE and CORE2, are registered publicly for anyone who wants the trial details.
No one should stop or change a prescribed lipid medication based on a news article. Dietary changes for this condition, including limits on fat and alcohol, are meaningful but need to be set by a clinician who knows the individual case rather than adopted from general advice. Exercise choices matter too, and MedicalDaily has reported that different workouts suited different metabolic markers.
Longer-term safety and outcomes data are expected as the drug is used more widely. MedicalDaily will track coverage decisions and any new safety findings.
Key Questions Answered
What was approved? Tryngolza, generically olezarsen, for adults with severe hypertriglyceridemia, to reduce triglycerides and the risk of acute pancreatitis alongside diet. The FDA cleared the broader indication in late June.
What counts as severe hypertriglyceridemia? Fasting triglycerides of at least 500 mg/dL. Normal levels are below 150 mg/dL.
How well did it work? Placebo-adjusted triglyceride reductions ranged from roughly 49 to 72 percent depending on dose at six months. The manufacturer reported an 85 percent pooled reduction in pancreatitis events at twelve months.
What are the side effects? Injection-site reactions and liver enzyme increases were most common. The label also warns about increased liver fat and hypersensitivity reactions.
How is it taken? A once-monthly injection under the skin by autoinjector, self-administered after training.
Does everyone with high triglycerides qualify? No. The indication targets the severe range. Most people with mildly elevated triglycerides fall well below the threshold.
When is abdominal pain an emergency? Severe pain radiating to the back with nausea, vomiting or fever warrants urgent evaluation, since it can indicate acute pancreatitis.
